NanoProstin Group, LLC
A wholly-owned company by Summers Medical Consultants, LLC
David P. Summers, MBA, Ph.D., FACA
Inventor, Designer, and Developer for the new Nano/Lipo PGE1-9
Diagnostics & Therapeutics
David P. Summers Ph.D Patent Information
Transdermal Delivery of Pharmaceutical Agents
​
Abstract
A method of administering a pharmaceutical agent to the circulatory system through the skin of a mammal may include the steps of loading a pharmaceutical agent in a transdermal patch, applying the transdermal patch to the skin of the mammal and releasing the pharmaceutical agent into the circulatory system at a rate of at least 0.001 micrograms per hour up to 50.0 micrograms per hour per kilogram of bodyweight of the mammal. The drug delivery system may comprise a transdermal patch loaded with the pharmaceutical agent. The patch may include a porous membrane and an outer impermeable cover defining a cavity therebetween. A plurality of drug delivery layers may be disposed between the porous membrane and the impermeable cover. A lipophilic/hydrophilic suspension may be disposed between the drug delivery layers.
Method For Treating Vascular Disease by administering Liposomal Prostaglandin Composition
​
United States Patent 9,962,393 Summers May 8, 2018
Method for treating vascular disease by administering a liposomal prostaglandin composition.
​
Abstract
In a multilamellar liposome, a pharmaceutical agent is encapsulated in the liposome in the absence of a partition enhancing buffer. Preferably, the pharmaceutical agent is prostaglandin E1 (PGE1). The pharmaceutical agent may be administered to a mammal in an amount effective to treat vascular disease. The release of the pharmaceutical agent from the multilamellar liposome may be regulated by proper selection of liposome size, dosage of the pharmaceutical agent, lipid to pharmaceutical agent weight ratio, and rate of infusion of the pharmaceutical agent.
